[
  {
    "ts": null,
    "headline": "GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises",
    "summary": "GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.",
    "url": "https://finnhub.io/api/news?id=2fe908c5d00ee70597cedb686fbcd1f93ca004941ac6b1547d0001f88728beb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753894260,
      "headline": "GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises",
      "id": 136149066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.",
      "url": "https://finnhub.io/api/news?id=2fe908c5d00ee70597cedb686fbcd1f93ca004941ac6b1547d0001f88728beb2"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 25.26%: Read This Before Placing a Bet",
    "summary": "The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
    "url": "https://finnhub.io/api/news?id=0b4e9c566f9ee485de0a4166048c349e7f6ed44d069a232783aef32afcb01fdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753883701,
      "headline": "Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 25.26%: Read This Before Placing a Bet",
      "id": 136149864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
      "url": "https://finnhub.io/api/news?id=0b4e9c566f9ee485de0a4166048c349e7f6ed44d069a232783aef32afcb01fdc"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical: Q2 Earnings Suggest Recovery",
    "summary": "West Pharmaceutical: Q2 Earnings Suggest Recovery",
    "url": "https://finnhub.io/api/news?id=227d475c19a74af0a83b153149d71668ac4d416e10e9bdbdb4d8265b74f5b974",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753878017,
      "headline": "West Pharmaceutical: Q2 Earnings Suggest Recovery",
      "id": 136133330,
      "image": "",
      "related": "WST",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=227d475c19a74af0a83b153149d71668ac4d416e10e9bdbdb4d8265b74f5b974"
    }
  },
  {
    "ts": null,
    "headline": "Baron Asset Fund Q2 2025 Shareholder Letter",
    "summary": "Baron Asset Fund Q2 2025 Shareholder Letter",
    "url": "https://finnhub.io/api/news?id=dbe0dc88135b6e8feb9461b089eae90339fbdb6d2f106752e4a497f62c2dd9a3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753844700,
      "headline": "Baron Asset Fund Q2 2025 Shareholder Letter",
      "id": 136127936,
      "image": "",
      "related": "WST",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=dbe0dc88135b6e8feb9461b089eae90339fbdb6d2f106752e4a497f62c2dd9a3"
    }
  }
]